Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PATHWAY: A Phase 1b/2a, Multicenter, Open- Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06785636 is registered in ClinicalTrials.gov with Pathos AI, Inc. as lead sponsor.

NCT NCT06785636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06785636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PATHWAY: A Phase 1b/2a, Multicenter, Open- Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Pathos AI, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 7, 2025
Completion date
April 30, 2029
Enrollment
120 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc (metastatic castration-resistant prostate cancer), prostate cancer